A New Stage Classification of Pancreatic Cancer Including Cytomolecular Factors

包括细胞分子因素的胰腺癌新分期分类

• 批准号: 08457301
• 负责人: TAMURA Katsuhiro
• 金额: $ 4.67万
• 依托单位: Shimane Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 1996
• 资助国家: 日本
• 起止时间: 1996 至 1997
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08457301/
• 关键词: pancreatic cancer; clinical stage; oncogene; tumor suppressor gene; growth factor; prognostic factor

The present project was designed to develope a new clinical stage classification of pancreatic cancer. The previous classification included just clinicopathological factors, but pancreatic cancer can not always be classified by this standard stage, because pancreatic cancer shows extremely malignant potentials. In the present study, we assessed the cytomolecular backgrounds of pancreatic cancer using various gene techniques and immunohistochemistry with monoclonal antibodies. The cytomolecular factors included Ki-ras point mutation and the expression of p53 tumor suppressor gene product, EGF and its receptor, fibronectin and Ki-ras p21.The results show that the expression of p53 tumor suppressor gene product, coexpression of EGF and EGF-receptor, and Ki-ras double mutation were suggested to be the indicators for poor prognosis of the patients with pancreatic cancer, independently of clinicopathological factors such as depth of tumor invasion, nodal involvement or distant metastasis.We conclude that these cytomolecular parameters are beneficial to predict the prognosis of the pancreatic cancer patients and the clinical stage should include the status of these parameters.

本项目旨在发展一种新的胰腺癌临床分期分类。先前的分类仅包括临床病理因素，但胰腺癌不能总是按这一标准分期进行分类，因为胰腺癌具有极恶性的潜力。在本研究中，我们使用各种基因技术和单克隆抗体免疫组织化学来评估胰腺癌的细胞分子背景。细胞分子因素包括Ki-ras点突变和肿瘤抑制基因产物p53、EGF及其受体、纤维连接蛋白和Ki-ras p21的表达。结果提示，p53抑癌基因产物的表达、EGF与EGF受体的共表达、Ki-ras双突变是胰腺癌患者预后不良的指标，与肿瘤浸润深度、淋巴结受累或远处转移等临床病理因素无关。我们认为这些细胞分子参数有助于预测胰腺癌患者的预后，临床分期应包括这些参数的状态。

项目成果

Mao-Min Song 他: "Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human parfcreas" International Journal of Pancreatology. 20・2. 85-93 (1997)

Mao-Min Song 等人：“Ki-ras 点突变和 p21 表达在人类胰腺良性和恶性外分泌肿瘤中的临床病理学意义”国际胰腺学杂志 20・2（1997）。

三成 善光 他: "膵癌におけるThymidine phosphorylase発現の免疫組織学的検討とその臨床病理学的意義" 日本癌治療学会誌. 32.4. 315-325 (1997)

Yoshimitsu Mitsunari 等人：“胰腺癌中胸苷磷酸化酶表达的免疫组织学检查及其临床病理学意义”，日本癌症治疗学会杂志 32.4（1997）。

Yoshinori Nio 他: "Ki-ras point mutation in codon 12 and expression of p53 in mucin-producing tumor of the pancreas" Journal Hepato-Biliary Pancreatic Surgery. 4・1. 83-90 (1997)

Yoshinori Nio 等人：“胰腺产生粘蛋白的肿瘤中密码子 12 的 Ki-ras 点突变和 p53 的表达”《肝胆胰外科杂志》4·1（1997 年）。

Mao-Min Song 他: "Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas" International Journal of Pancreatology. 20.2. 85-93 (1997)

Mao-Min Song 等人：“Ki-ras 点突变和 p21 表达在人类胰腺良性和恶性外分泌肿瘤中的临床病理学意义”国际胰腺学杂志 20.2（1997）。

Mao-Min Song, et al.: "Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas" International Journal of Pancreatology. 20 (2). 85-93 (1997)

Mao-Min Song 等人：“Ki-ras 点突变和 p21 表达在人类胰腺良性和恶性外分泌肿瘤中的临床病理学意义”国际胰腺学杂志。